What is HC Wainwright’s Estimate for HRTX FY2026 Earnings?

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Investment analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of Heron Therapeutics in a note issued to investors on Wednesday, November 11th. HC Wainwright analyst B. Folkes now expects that the biotechnology company will earn ($0.15) per share for the year, down from their prior forecast of ($0.14). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Heron Therapeutics’ Q4 2026 earnings at ($0.04) EPS, FY2027 earnings at ($0.14) EPS, FY2028 earnings at ($0.09) EPS and FY2029 earnings at ($0.03) EPS.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Monday, November 9th. The biotechnology company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $35.25 million for the quarter, compared to analysts’ expectations of $37.50 million. Heron Therapeutics had a negative return on equity of 277.36% and a negative net margin of 14.55%.

A number of other brokerages have also commented on HRTX. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, October 15th. Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Wall Street Zen raised shares of Heron Therapeutics to a “sell” rating in a report on Saturday, August 8th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $2.00.

Heron Therapeutics Trading Down 9.3%

Shares of HRTX stock opened at $0.33 on Friday. The company has a debt-to-equity ratio of 32.59, a quick ratio of 1.51 and a current ratio of 2.33. Heron Therapeutics has a 1 year low of $0.26 and a 1 year high of $1.57. The stock has a fifty day moving average of $0.33 and a two-hundred day moving average of $0.65. The firm has a market capitalization of $62.01 million, a PE ratio of -2.72 and a beta of 1.65.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HRTX. Orbimed Advisors LLC acquired a new position in shares of Heron Therapeutics during the first quarter valued at approximately $7,855,000. BlackRock Inc. bought a new stake in Heron Therapeutics during the second quarter worth approximately $4,503,000. Tejara Capital Ltd acquired a new stake in Heron Therapeutics in the second quarter worth approximately $2,779,000. Pale Fire Capital SE lifted its position in Heron Therapeutics by 84.8% in the first quarter. Pale Fire Capital SE now owns 2,716,328 shares of the biotechnology company’s stock worth $2,173,000 after purchasing an additional 1,246,673 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in Heron Therapeutics in the second quarter worth approximately $445,000. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting. The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.